Study of Linx Reflux Management System demonstrates benefits in GERD- Torax Medical
Torax Medical announced completion of a landmark study confirming the long-term results of the Linx Reflux Management System in controlling reflux-related symptoms and eliminating dependence on acid suppression medications called proton pump inhibitors (PPIs) in patients with gastro-esophageal reflux disease (GERD). Findings from the clinical study demonstrated that the Linx procedure normalized the amount of acid in the esophagus, while safely and effectively relieving heartburn and regurgitation, and improving quality of life without the need for PPIs.
The Linx device was approved by the FDA in early 2012 and is currently the only medical device approved by the FDA to be safe and effective for the treatment of GERD. Authors of the clinical study, published this week in a leading medical journal; Clinical Gastroenterology and Hepatology concluded LINX should now be considered a first-line anti-reflux therapy for appropriate patients.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma